Brought to you by 
Astellas, Potenza ally in immuno-oncology therapies; Astellas later acquires company
02 Aug 2022
Executive Summary
Astellas Pharma Inc. and Potenza Therapeutics Inc. teamed up to discover and develop cancer immunotherapies that target immune checkpoint pathways, co-stimulatory signals, and regulatory T cells.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes M&A Option
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Astellas, Potenza ally in immuno-oncology therapies; Astellas later acquires company
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice